Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Наслов
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Идентификатор
/unibl/sci/idNaucniRad:24623
Тип
Пронађите сличне уносеAcademic Article
Датум
Пронађите сличне уносе2017-07
Библиографски цитат
R. Fleischmann, E. Mysler, S. Hall, A. Kivitz, R. Moots, Z. Luo, R. DeMasi, K. Soma, R. Zhang, L. Takiya, S. Tatulych, C. Mojcik, S. Krishnaswami, S. Menon, J. Smolen, LJ. Božić, Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial, LANCET, THE, pp. 457 - 468, Jul, 2017
Почетна страница
457
Крајња страница
468
Је дио
Пронађите сличне уносеLANCET, THE
Пронађите сличне уносе0140-6736
Листа аутора
Position: 3132 (172 views)